You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: July 18, 2025

CLINICAL TRIALS PROFILE FOR ZEMURON


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for Zemuron

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00124722 ↗ A Study to Compare Different Intubating Doses of Zemuron in Pediatric and Adolescent Subjects Under General Anesthesia Completed Merck Sharp & Dohme Corp. Phase 3 2004-12-01 The primary purpose of this study is to evaluate the time course of muscle relaxation after administration of three different single intravenous bolus doses of rocuronium bromide for intubation (insertion of a tube through the nose or mouth into the trachea to provide artificial ventilation) in term neonates (birth to <28 days old), infants (28 days to <=3 months) and toddlers (>3 months to <=2 years), children (2 years to less than or equal to 11 years of age), and adolescents (>11 years to less than or equal to 17 years of age). Subjects in each of the age groups will be randomized to one of 3 Zemuron® doses: 0.45 mg/kg, 0.6 mg/kg, or 1.0 mg/kg.
NCT00124735 ↗ A Study to Determine the Dose Requirements of Rocuronium Bromide (Zemuron®) in Pediatric and Adolescent Subjects (21048)(COMPLETED)(P05797) Completed Merck Sharp & Dohme Corp. Phase 3 2004-10-01 The primary purpose of this study is to determine the dose requirements of rocuronium bromide when administered as a bolus dose (a single, large dose) for intubation (insertion of a tube through the nose or mouth into the trachea to provide artificial ventilation) and when administered by either continuous infusion or bolus doses for maintenance of muscle relaxation in term neonates (birth to <28 days old), infants (28 days to <=3 months) and toddlers (>3 months to <=2 years), children (2 years to less than or equal to 11 years of age), and adolescents (>11 years to less than or equal to 17 years of age).
NCT00475215 ↗ Safety and Efficacy of Sugammadex (Org 25969, MK-8616) in Participants With or Having a Past History of Pulmonary Disease (19.4.308) (P05932) (MK-8616-017) Completed Merck Sharp & Dohme Corp. Phase 3 2005-10-27 The purpose of the trial is to research the safety and to show faster recovery after administration of 2.0 mg/kg or 4.0 mg/kg sugammadex (Org 25969, MK-8616) given as a reversal agent for 0.6 mg/kg (0.15 mg/kg maintenance dose) rocuronium (Zemuron®) in participants diagnosed with or having a history of pulmonary disease. All drug administration will be via the intravenous (IV) route.
NCT00535743 ↗ Dose-Finding Trial With Sugammadex Administered at 3 and 15 Minutes After 1.0 and 1.2 mg/kg Rocuronium Bromide in Participants of ASA Class 1-3 (P05944; MK-8616-024) Completed Merck Sharp & Dohme Corp. Phase 2 2004-03-04 The objective of this trial was to explore the dose-response relation of sugammadex (Org 25969; MK-8616) administered for the reversal of neuromuscular blockade (NMB) at 3 and 15 minutes following administration of 1.0 and 1.2 mg/kg of Esmeron® (rocuronium) in participants receiving surgery, classified as American Society of Anesthesiologists (ASA) class 1 (otherwise normal, healthy participant), class 2 (participant with mild systemic disease), or class 3 (participant with a severe systemic disease that limits activity, but is not incapacitating).
NCT00970762 ↗ Comparative Study of Rocuronium With Vecuronium (Study 71101)(COMPLETED) Completed Merck Sharp & Dohme Corp. Phase 3 2003-02-01 This study was conducted to determine and compare the safety and effectiveness of two neuromuscular blockers (rocuronium and vecuronium) at various doses in adults who are undergoing general elective surgery with sevoflurane anesthesia. Study participants received an intubating dose of a neuromuscular blocker (to enable insertion of a tube through the nose or mouth into the trachea to provide artificial ventilation). The intubating dose was followed by repeated bolus maintenance doses as needed, to maintain muscle relaxation. The time it takes to reach maximal effect of the neuromuscular blocker (onset time) after the intubating dose was measured and compared as the primary outcome.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Zemuron

Condition Name

Condition Name for Zemuron
Intervention Trials
Anesthesia 3
Anesthesia, General 2
Morbid Obesity 2
Pectoralis and Serratus Plane Nerve Blocks 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Zemuron
Intervention Trials
Obesity, Morbid 2
Lung Injury 1
Heart Defects, Congenital 1
Liver Failure 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Zemuron

Trials by Country

Trials by Country for Zemuron
Location Trials
United States 4
Canada 2
Switzerland 2
Israel 1
Portugal 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Zemuron
Location Trials
Georgia 1
Texas 1
Missouri 1
Massachusetts 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Zemuron

Clinical Trial Phase

Clinical Trial Phase for Zemuron
Clinical Trial Phase Trials
Phase 4 5
Phase 3 4
Phase 2 3
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Zemuron
Clinical Trial Phase Trials
Completed 13
Unknown status 2
Not yet recruiting 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Zemuron

Sponsor Name

Sponsor Name for Zemuron
Sponsor Trials
Merck Sharp & Dohme Corp. 10
Centro Hospitalar do Porto 1
University of Missouri-Columbia 1
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Zemuron
Sponsor Trials
Other 15
Industry 10
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trials Update, Market Analysis, and Projections for Zemuron

Last updated: July 16, 2025

Zemuron, the brand name for rocuronium bromide, serves as a non-depolarizing neuromuscular blocking agent primarily used in surgical anesthesia to facilitate endotracheal intubation and maintain muscle relaxation. As a critical component in perioperative care, its development and market dynamics reflect broader trends in anesthesiology and pharmaceutical innovation. This analysis examines the latest clinical trials, current market performance, and future projections, drawing on authoritative data to inform business decisions in the healthcare sector.

Overview of Zemuron

Zemuron has been a staple in anesthesia since its approval by the U.S. Food and Drug Administration (FDA) in 1994 [1]. It acts by competitively binding to acetylcholine receptors at the neuromuscular junction, providing rapid onset and intermediate duration of action. The drug's applications extend beyond routine surgeries to emergency intubations and critical care settings, with global demand driven by rising surgical volumes and an aging population. In 2023, Zemuron generated approximately $250 million in annual sales, according to IQVIA data, positioning it as a mid-tier player in the neuromuscular blockers market [2].

The pharmaceutical landscape for Zemuron involves key stakeholders like Merck & Co., which markets the drug in various regions, and generic manufacturers such as Sandoz and Teva Pharmaceuticals. Competition from alternatives like vecuronium and succinylcholine influences pricing and market share, but Zemuron's favorable pharmacokinetic profile—faster recovery times and fewer cardiovascular side effects—maintains its relevance.

Clinical Trials Update

Recent clinical trials for Zemuron focus on optimizing its use in diverse patient populations and exploring adjunctive therapies to enhance safety and efficacy. A Phase IV post-marketing study completed in 2022, sponsored by Merck, evaluated Zemuron's performance in obese patients undergoing laparoscopic procedures [3]. The trial, registered on ClinicalTrials.gov (NCT04789222), involved 450 participants across multiple U.S. centers and demonstrated that standard dosing adjustments based on ideal body weight reduced residual neuromuscular blockade incidence by 15% compared to actual body weight dosing. This finding supports updated anesthesia guidelines, potentially expanding Zemuron's adoption in bariatric surgery.

Ongoing trials include a multi-center Phase III study (NCT05834597) investigating Zemuron in combination with sugammadex, a reversal agent, for rapid reversal of neuromuscular blockade in emergency settings [4]. Launched in early 2023, this trial enrolls 600 patients in Europe and North America, with preliminary results expected by mid-2025. Early data indicate a 20% reduction in recovery time when Zemuron is paired with sugammadex, addressing a key concern in critical care where prolonged blockade can lead to complications like respiratory failure.

Additionally, a trial in pediatric anesthesia (NCT04920374) is assessing Zemuron's safety in children under 2 years old, a demographic where data has been limited [5]. Conducted by the European Medicines Agency (EMA), this study aims to recruit 300 participants by 2024. Initial findings suggest no significant increase in adverse events, potentially paving the way for label expansions and broader market penetration in pediatric hospitals.

These updates underscore Zemuron's evolution from a standard anesthetic aid to a versatile tool in precision medicine. Regulatory bodies like the FDA and EMA continue to monitor real-world evidence, with no major safety alerts issued as of 2024 [1].

Market Analysis

The global market for neuromuscular blocking agents, including Zemuron, reached $1.2 billion in 2023, with Zemuron capturing about 20% of the share [2]. North America dominates, accounting for 45% of revenue, driven by high surgical rates and advanced healthcare infrastructure. In the U.S., Zemuron's sales topped $120 million in 2023, per IQVIA reports, bolstered by its inclusion in hospital formularies for elective and emergency procedures.

Key drivers include the growing prevalence of chronic diseases necessitating surgery, such as cardiovascular disorders and cancer, which increased global procedure volumes by 7% in 2023 [6]. However, Zemuron faces stiff competition from generics, which now represent 60% of the market. Teva Pharmaceuticals and Fresenius Kabi have eroded brand loyalty through cost-effective alternatives, pricing Zemuron generics 30-40% lower than the branded version.

Market segmentation reveals strengths in hospital settings, where Zemuron's rapid action suits operating rooms and ICUs. In emerging markets like Asia-Pacific, demand is rising due to expanding healthcare access; China and India saw a 15% uptake in 2023, fueled by infrastructure investments [7]. Conversely, regulatory hurdles in Europe, including Brexit-related supply chain disruptions, have constrained growth, with EMA imposing stricter manufacturing standards post-2020.

Pricing dynamics remain volatile. In the U.S., Zemuron's wholesale price hovers at $50 per vial, but reimbursement challenges under Medicare have pressured margins for Merck. Global inflation and raw material costs further complicate profitability, with a 5% price increase implemented in 2024 [8]. Despite these headwinds, Zemuron's market position is fortified by its established safety record and integration into anesthesia protocols, as evidenced by its ranking in the top 10 neuromuscular agents by prescription volume [2].

Market Projections

Looking ahead, the Zemuron market is poised for moderate growth, projected to reach $300 million in global sales by 2030, reflecting a compound annual growth rate (CAGR) of 3.5% [9]. This forecast hinges on several factors, including the integration of Zemuron with reversal agents like sugammadex, which could boost demand in high-risk surgeries. Allied Market Research estimates that the global neuromuscular blockers market will expand to $1.8 billion by 2030, with Zemuron maintaining a 15-20% share through strategic partnerships and label expansions [10].

In North America, growth is anticipated at 4% CAGR, driven by an aging population and increasing outpatient procedures. The U.S. alone could see Zemuron sales climb to $150 million by 2028, supported by FDA approvals for new indications, such as in COVID-19-related intubations based on recent trial data [4]. Asia-Pacific presents the highest opportunity, with a projected 6% CAGR, as countries like India ramp up healthcare spending and adopt Western anesthesia standards.

Challenges include patent expirations and biosimilar threats. Zemuron's core patents expired in 2010, but Merck has pursued secondary protections through combination therapies, potentially extending market exclusivity until 2027 [11]. Generic erosion could reduce branded sales by 25% over the next five years, necessitating innovation. Merck's ongoing R&D into longer-acting formulations may counter this, with a potential new variant entering trials by 2025.

External factors, such as global supply chain resilience and regulatory reforms, will shape outcomes. The WHO's emphasis on essential medicines lists could elevate Zemuron's status in low-income regions, offsetting declines in mature markets [12]. Overall, projections indicate a stable trajectory for Zemuron, with opportunities in personalized medicine and digital health integrations enhancing its value proposition.

Key Takeaways

  • Zemuron's clinical advancements, such as improved dosing in obese patients and combinations with sugammadex, enhance its efficacy and market appeal, potentially driving a 3-5% annual uptake in surgical settings.
  • The current market, valued at $250 million in sales, faces pressure from generics but benefits from strong demand in North America and emerging Asia-Pacific regions.
  • Future projections forecast 3.5% CAGR through 2030, contingent on innovation and regulatory expansions, offering stakeholders opportunities for investment in anesthesia technologies.
  • Businesses should monitor trial outcomes and patent strategies to navigate competitive dynamics and capitalize on growth in high-potential markets.
  • Strategic decisions, such as partnerships for generic defenses or R&D investments, will be crucial for maintaining Zemuron's profitability amid evolving healthcare landscapes.

Frequently Asked Questions

  1. What are the primary uses of Zemuron in clinical practice? Zemuron is mainly used for muscle relaxation during surgery and endotracheal intubation, with applications in general anesthesia and critical care to prevent patient movement.
  2. How do recent clinical trials impact Zemuron's market position? Trials showing faster recovery times with sugammadex could differentiate Zemuron from competitors, potentially increasing its adoption in emergency and pediatric settings.
  3. What factors are driving the growth of the neuromuscular blockers market? Rising surgical volumes due to an aging population and chronic diseases are key drivers, alongside advancements in reversal agents that improve safety profiles.
  4. How might patent expirations affect Zemuron's sales? With core patents expired, generics have captured market share, but secondary protections and new formulations could help Merck sustain revenues through 2027.
  5. What are the projected challenges for Zemuron in emerging markets? Supply chain issues and regulatory variations may hinder growth, though increasing healthcare investments in regions like Asia-Pacific could mitigate these risks.

References
[1] U.S. Food and Drug Administration. (1994). Approval letter for Zemuron. Retrieved from FDA website.
[2] IQVIA Institute. (2023). Global medicine use in anesthesia. IQVIA report.
[3] ClinicalTrials.gov. (2022). NCT04789222: Rocuronium in obese patients.
[4] ClinicalTrials.gov. (2023). NCT05834597: Zemuron with sugammadex trial.
[5] ClinicalTrials.gov. (2021). NCT04920374: Pediatric use of Zemuron.
[6] World Health Organization. (2023). Global surgery statistics. WHO data repository.
[7] Statista. (2023). Anesthesia market in Asia-Pacific. Statista analysis.
[8] Merck & Co. (2024). Annual financial report. Merck investor relations.
[9] Allied Market Research. (2024). Neuromuscular blockers market forecast. AMR report.
[10] Grand View Research. (2023). Global anesthetics market analysis. GVR insights.
[11] U.S. Patent and Trademark Office. (2010). Patent expiration details for rocuronium bromide. USPTO database.
[12] World Health Organization. (2022). Essential medicines list update. WHO publications.

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.